Tags

Type your tag names separated by a space and hit enter

Febuxostat for prevention of gout attacks.

Abstract

(1) Febuxostat is a selective inhibitor of xanthine oxidase. Its use in the management of hyperuricemia and gout is being studied. (2) In a 52-week, phase III randomized clinical trial, febuxostat was superior to allopurinol for lowering uric acid levels. Its efficacy in preventing gout attacks was similar to that of allopurinol. Despite a similar rate of adverse effects, individuals on febuxostat were more likely to stop treatment than those on allopurinol. (3) The most commonly observed adverse effects with febuxostat include liver function test abnormalities, diarrhea, headache, nausea, vomiting, abdominal pain, and dizziness. (4) Given that renal dysfunction is a risk factor for hyperuricemia and gout, the safety and efficacy of febuxostat in this population should be considered, but only limited data are available. (5) The diffusion of febuxostat may be limited by its price relative to that of allopurinol, regardless of whether febuxostat proves to have advantages in specific populations.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16958189

Citation

Pohar, S, and G Murphy. "Febuxostat for Prevention of Gout Attacks." Issues in Emerging Health Technologies, 2006, pp. 1-4.
Pohar S, Murphy G. Febuxostat for prevention of gout attacks. Issues Emerg Health Technol. 2006.
Pohar, S., & Murphy, G. (2006). Febuxostat for prevention of gout attacks. Issues in Emerging Health Technologies, (87), 1-4.
Pohar S, Murphy G. Febuxostat for Prevention of Gout Attacks. Issues Emerg Health Technol. 2006;(87)1-4. PubMed PMID: 16958189.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Febuxostat for prevention of gout attacks. AU - Pohar,S, AU - Murphy,G, PY - 2006/9/9/pubmed PY - 2006/9/16/medline PY - 2006/9/9/entrez SP - 1 EP - 4 JF - Issues in emerging health technologies JO - Issues Emerg Health Technol IS - 87 N2 - (1) Febuxostat is a selective inhibitor of xanthine oxidase. Its use in the management of hyperuricemia and gout is being studied. (2) In a 52-week, phase III randomized clinical trial, febuxostat was superior to allopurinol for lowering uric acid levels. Its efficacy in preventing gout attacks was similar to that of allopurinol. Despite a similar rate of adverse effects, individuals on febuxostat were more likely to stop treatment than those on allopurinol. (3) The most commonly observed adverse effects with febuxostat include liver function test abnormalities, diarrhea, headache, nausea, vomiting, abdominal pain, and dizziness. (4) Given that renal dysfunction is a risk factor for hyperuricemia and gout, the safety and efficacy of febuxostat in this population should be considered, but only limited data are available. (5) The diffusion of febuxostat may be limited by its price relative to that of allopurinol, regardless of whether febuxostat proves to have advantages in specific populations. SN - 1488-6316 UR - https://www.unboundmedicine.com/medline/citation/16958189/Febuxostat_for_prevention_of_gout_attacks_ L2 - https://medlineplus.gov/gout.html DB - PRIME DP - Unbound Medicine ER -